Table 1.
Clinical and molecular characteristics of patients in different treatment groups
| Characteristics | Chemotherapy‐only group | Allo‐HSCT group | ||||
|---|---|---|---|---|---|---|
| High DDIT4 (n = 42) | Low DDIT4 (n = 42) | P | High DDIT4 (n = 35) | Low DDIT4 (n = 36) | P | |
| Age/years, median (range) | 70 (35‐88) | 63 (22‐82) | .003a | 53 (18‐72) | 50 (21‐65) | .411a |
| Age group/n (%) | ||||||
| <60 y | 8 (19.0) | 18 (42.9) | .018b | 23 (65.7) | 29 (80.6) | .158b |
| ≥60 y | 34 (81.0) | 24 (57.1) | 12 (34.3) | 7 (19.4) | ||
| Gender/n (%) | ||||||
| Male | 25 (59.5) | 20 (47.6) | .274b | 20 (57.1) | 21 (58.3) | .919b |
| Female | 17 (40.5) | 22 (52.4) | 15 (42.9) | 15 (41.7) | ||
| WBC/×109/L, median (range) | 13.3 (1.0‐297.4) | 16.1 (0.7‐171.9) | .522a | 34.2 (0.6‐223.8) | 29.4 (0.9‐115.4) | .761a |
| BM blast/%, median (range) | 77 (32‐99) | 66 (30‐95) | .041a | 72 (30‐100) | 70 (34‐99) | .913a |
| PB blast/%, median (range) | 22 (0‐98) | 25 (0‐91) | .449a | 53 (0‐96) | 45 (0‐94) | .366a |
| FAB subtypes/n (%) | ||||||
| M0 | 7 (16.7) | 0 (0.0) | .012b | 4 (11.4) | 5 (13.9) | .755b |
| M1 | 10 (23.8) | 10 (23.8) | 1.000b | 17 (48.6) | 6 (16.7) | .004b |
| M2 | 7 (16.7) | 14 (33.3) | .078b | 9 (25.7) | 9 (25.0) | 1.000b |
| M3 | 0 (0.0) | 0 (0.0) | 1.000b | 0 (0.0) | 1 (2.8) | .493b |
| M4 | 8 (19.0) | 12 (28.6) | .306b | 1 (2.9) | 12 (33.3) | .001b |
| M5 | 6 (14.3) | 6 (14.3) | 1.000b | 2 (5.7) | 2 (5.6) | 1.000b |
| M6 | 1 (2.4) | 0 (0.0) | 1.000b | 1 (2.9) | 0 (0.0) | .493b |
| M7 | 3 (7.1) | 0 (0.0) | .241b | 1 (2.9) | 1 (2.8) | 1.000b |
| Cytogenetics/n (%) | ||||||
| Normal | 19 (45.2) | 21 (50.0) | .662b | 18 (51.4) | 15 (41.7) | .410b |
| Complex karyotype | 9 (21.4) | 2 (4.8) | .048b | 9 (25.7) | 2 (5.6) | .019b |
| 8 Trisomy | 0 (0.0) | 0 (0.0) | 1.000b | 3 (8.6) | 3 (8.3) | 1.000b |
| inv(16)/CBFβ‐MYH11 | 0 (0.0) | 6 (14.3) | .026b | 0 (0.0) | 5 (13.9) | .054b |
| 11q23/MLL | 1 (2.4) | 2 (4.8) | .614b | 1 (2.9) | 2 (5.6) | 1.000b |
| −7/7q‐ | 2 (4.8) | 1 (2.4) | .614b | 2 (5.7) | 1 (2.8) | .614b |
| t(15;17)/PML‐RARA | 0 (0.0) | 0 (0.0) | 1.000b | 0 (0.0) | 1 (2.8) | 1.000b |
| t(9;22)/BCR‐ABL1 | 1 (2.4) | 0 (0.0) | 1.000b | 1 (2.9) | 1 (2.8) | 1.000b |
| t(8;21)/RUNX1‐RUNX1T1 | 0 (0.0) | 6 (14.3) | .026b | 0 (0.0) | 1 (2.8) | 1.000b |
| Others | 10 (23.8) | 4 (9.5) | .079b | 1 (2.9) | 5 (13.9) | .199b |
| Risk/n (%) | ||||||
| Good | 0 (0.0) | 12 (28.6) | .000b | 0 (0.0) | 7 (19.4) | .011b |
| Intermediate | 26 (61.9) | 20 (47.6) | .188b | 19 (54.3) | 21 (58.3) | .731b |
| Poor | 16 (38.1) | 10 (23.8) | .157b | 16 (45.7) | 8 (22.2) | .036b |
| FLT3‐ITD/n (%) | ||||||
| Positive | 6 (14.3) | 9 (21.4) | .393b | 9 (25.7) | 8 (22.2) | .730b |
| Negative | 36 (85.7) | 33 (78.6) | 26 (74.3) | 28 (77.8) | ||
| NPM1/n (%) | ||||||
| Mutation | 13 (31.0) | 14 (13.3) | .815b | 9 (25.7) | 9 (25.0) | .945b |
| Wild type | 29 (69.0) | 28 (66.7) | 26 (74.3) | 27 (75.0) | ||
| DNMT3A/n (%) | ||||||
| Mutation | 12 (28.6) | 11 (26.2) | .807b | 10 (28.6) | 7 (19.4) | .368b |
| Wild type | 30 (71.4) | 31 (73.8) | 25 (71.4) | 29 (80.6) | ||
| IDH1/IDH2/n (%) | ||||||
| Mutation | 9 (21.4) | 6 (14.3) | .393b | 11 (31.4) | 6 (16.7) | .145b |
| Wild type | 33 (78.6) | 36 (85.7) | 24 (68.6) | 30 (83.3) | ||
| RUNX1/n (%) | ||||||
| Mutation | 12 (28.6) | 2 (4.8) | .003b | 3 (8.6) | 5 (13.9) | .710b |
| Wild type | 30 (71.4) | 42 (95.2) | 32 (91.4) | 31 (86.1) | ||
| NRAS/KRAS/n (%) | ||||||
| Mutation | 6 (14.3) | 6 (14.3) | 1.000b | 1 (2.9) | 6 (16.7) | .107b |
| Wild type | 36 (85.7) | 36 (85.7) | 34 (97.1) | 30 (83.3) | ||
| TET2/n (%) | ||||||
| Mutation | 4 (9.5) | 7 (16.7) | .332b | 0 (0.0) | 4 (11.1) | .115b |
| Wild type | 38 (90.5) | 35 (83.3) | 35 (100) | 32 (88.9) | ||
| TP53/n (%) | ||||||
| Mutation | 9 (21.4) | 2 (4.8) | .024b | 3 (8.6) | 1 (2.8) | .357b |
| Wild type | 33 (78.6) | 40 (95.2) | 32 (91.4) | 35 (97.2) | ||
Abbreviations: BM, bone marrow; FAB, French‐American‐British; PB, peripheral blood; WBC, white blood cell.
a
Denotes Mann‐Whitney U test
b
Denotes chi‐square test.